Treatment options for chronic myeloid leukemia

Maria Florencia Tanaka, Hagop Kantarjian, Jorge Cortes, Maro Ohanian, Elias Jabbour

Research output: Contribution to journalReview article

Abstract

Introduction : The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. Areas covered : The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to monitor the disease and a brief read of special populations and case scenarios. It describes the first-line (imatinib) and second-line (nilotinib and dasatinib) TKIs currently used for the treatment of CML, including landmark studies proving their efficacy, side effect profile, dosage and use in special populations. It also reviews the current guidelines regarding treatment and monitoring of the disease while on TKIs, along with an overview of treatment in advanced stages, the role of allogeneic stem cell transplantation and investigational drugs. Expert opinion : Although imatinib represented a mayor therapeutic advancement over conventional chemotherapy, second-generation TKIs offer higher rates of optimal response and should be used as the frontline therapy. Patients with the T315I mutation carry a worse prognosis and should be offered allogeneic stem cell transplantation. The treatment in advanced stages of CML remains suboptimal and bench, translational and clinical research is encouraged.

Original languageEnglish (US)
Pages (from-to)815-828
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number6
DOIs
StatePublished - Apr 1 2012

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Stem Cell Transplantation
Therapeutics
bcr-abl Fusion Proteins
Investigational Drugs
Translational Medical Research
Expert Testimony
Population
Guidelines
Drug Therapy
Mutation

Keywords

  • Chronic Myeloid Leukemia
  • Dasatinib
  • Imatinib
  • Nilotinib
  • Treatment
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Treatment options for chronic myeloid leukemia. / Tanaka, Maria Florencia; Kantarjian, Hagop; Cortes, Jorge; Ohanian, Maro; Jabbour, Elias.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 6, 01.04.2012, p. 815-828.

Research output: Contribution to journalReview article

Tanaka, MF, Kantarjian, H, Cortes, J, Ohanian, M & Jabbour, E 2012, 'Treatment options for chronic myeloid leukemia', Expert Opinion on Pharmacotherapy, vol. 13, no. 6, pp. 815-828. https://doi.org/10.1517/14656566.2012.671296
Tanaka, Maria Florencia ; Kantarjian, Hagop ; Cortes, Jorge ; Ohanian, Maro ; Jabbour, Elias. / Treatment options for chronic myeloid leukemia. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 6. pp. 815-828.
@article{b8c4d68d19ab4c0eaa6943a7dbb8541b,
title = "Treatment options for chronic myeloid leukemia",
abstract = "Introduction : The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. Areas covered : The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to monitor the disease and a brief read of special populations and case scenarios. It describes the first-line (imatinib) and second-line (nilotinib and dasatinib) TKIs currently used for the treatment of CML, including landmark studies proving their efficacy, side effect profile, dosage and use in special populations. It also reviews the current guidelines regarding treatment and monitoring of the disease while on TKIs, along with an overview of treatment in advanced stages, the role of allogeneic stem cell transplantation and investigational drugs. Expert opinion : Although imatinib represented a mayor therapeutic advancement over conventional chemotherapy, second-generation TKIs offer higher rates of optimal response and should be used as the frontline therapy. Patients with the T315I mutation carry a worse prognosis and should be offered allogeneic stem cell transplantation. The treatment in advanced stages of CML remains suboptimal and bench, translational and clinical research is encouraged.",
keywords = "Chronic Myeloid Leukemia, Dasatinib, Imatinib, Nilotinib, Treatment, Tyrosine kinase inhibitors",
author = "Tanaka, {Maria Florencia} and Hagop Kantarjian and Jorge Cortes and Maro Ohanian and Elias Jabbour",
year = "2012",
month = "4",
day = "1",
doi = "10.1517/14656566.2012.671296",
language = "English (US)",
volume = "13",
pages = "815--828",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Treatment options for chronic myeloid leukemia

AU - Tanaka, Maria Florencia

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Ohanian, Maro

AU - Jabbour, Elias

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Introduction : The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. Areas covered : The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to monitor the disease and a brief read of special populations and case scenarios. It describes the first-line (imatinib) and second-line (nilotinib and dasatinib) TKIs currently used for the treatment of CML, including landmark studies proving their efficacy, side effect profile, dosage and use in special populations. It also reviews the current guidelines regarding treatment and monitoring of the disease while on TKIs, along with an overview of treatment in advanced stages, the role of allogeneic stem cell transplantation and investigational drugs. Expert opinion : Although imatinib represented a mayor therapeutic advancement over conventional chemotherapy, second-generation TKIs offer higher rates of optimal response and should be used as the frontline therapy. Patients with the T315I mutation carry a worse prognosis and should be offered allogeneic stem cell transplantation. The treatment in advanced stages of CML remains suboptimal and bench, translational and clinical research is encouraged.

AB - Introduction : The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. Areas covered : The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to monitor the disease and a brief read of special populations and case scenarios. It describes the first-line (imatinib) and second-line (nilotinib and dasatinib) TKIs currently used for the treatment of CML, including landmark studies proving their efficacy, side effect profile, dosage and use in special populations. It also reviews the current guidelines regarding treatment and monitoring of the disease while on TKIs, along with an overview of treatment in advanced stages, the role of allogeneic stem cell transplantation and investigational drugs. Expert opinion : Although imatinib represented a mayor therapeutic advancement over conventional chemotherapy, second-generation TKIs offer higher rates of optimal response and should be used as the frontline therapy. Patients with the T315I mutation carry a worse prognosis and should be offered allogeneic stem cell transplantation. The treatment in advanced stages of CML remains suboptimal and bench, translational and clinical research is encouraged.

KW - Chronic Myeloid Leukemia

KW - Dasatinib

KW - Imatinib

KW - Nilotinib

KW - Treatment

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84863373152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863373152&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.671296

DO - 10.1517/14656566.2012.671296

M3 - Review article

C2 - 22429140

AN - SCOPUS:84863373152

VL - 13

SP - 815

EP - 828

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -